{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.0","value":"53.1"}]}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.6","value":"59.0"}]}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Plasma concentrations of pomalidomide were assayed using high-performance liquid chromatography with fluorescence detection with a lower limit of quantitation of 1 ng/mL and were recorded as observed values. A non-compartmental analysis was used to calculate plasma pharmacokinetic parameters (Pharsight, Mountain View, California).","dispersionType":"Standard Deviation","groups":[{"description":"All participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG000","title":"All Participants - Pomalidomide 5mg Daily"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.","title":"Maximal Plasma Concentration (Cmax) of Pomalidomide","type":"PRIMARY","unitOfMeasure":"ng/mL"}